Overview

Safety and Tolerability of Ciclesonide and Formoterol Fumarate Inhaled Once Daily in Patients With Asthma (18 to 75 y) (BY9010/M1-506)

Status:
Completed

Trial end date:
2006-01-01

Target enrollment:

Participant gender:

Summary

The aim of the study is to compare the efficacy of two doses of a fixed combination of ciclesonide/formoterol fumarate versus ciclesonide alone versus formoterol fumarate alone in patients with asthma. The study duration consists of a baseline period (2 to 3 weeks) and a treatment period (8 weeks). The study will provide further data on safety and tolerability of ciclesonide/formoterol fumarate.

Phase:

Phase 2

Details

Lead Sponsor:

AstraZeneca

Treatments:

Ciclesonide
Formoterol Fumarate